Home
News
Create
Screeners
Insights
Sudeep Pharma
644.
20
+12.60
(+1.99%)
Market Cap
₹7,276.15 Cr
PE Ratio
41.87
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.99%
1M
+14.85%
6M
-16.79%
1Y
-16.79%
5Y
-16.79%
View Company Insights
Latest news about Sudeep Pharma
Sudeep Pharma Submits Q3FY26 Earnings Call Transcript Following Strong Results
Feb 07, 2026
Sudeep Pharma Limited submitted its Q3FY26 earnings call transcript to stock exchanges, detailing strong financial performance with 52% revenue growth and strategic initiatives including battery materials expansion. The earnings call provided comprehensive insights into the company's diversified growth across pharmaceutical, specialty ingredients, and emerging battery materials segments.
Sudeep Pharma Makes Q3FY26 Earnings Call Audio Recording Available Online
Feb 07, 2026
Sudeep Pharma Files Regulatory Notice for VP John Garcia's Resignation
Feb 05, 2026
Sudeep Pharma Subsidiary Acquires Gujarat Land Rights for ₹20.97 Crores Manufacturing Facility
Jan 22, 2026
Sudeep Pharma Limited Updates CIN and Company Status Following Stock Exchange Listing
Jan 16, 2026
More news about Sudeep Pharma
21
Dec 25
Sudeep Pharma Submits Q2FY26 Earnings Call Audio Recording to Stock Exchanges
Sudeep Pharma Limited has completed its Q2FY26 earnings call and submitted the audio recording to stock exchanges in compliance with SEBI regulations. The call was held on December 22, 2025, to discuss performance for the quarter and half-year ended September 30, 2025, with the recording now available on the company's website for stakeholder access.
19
Dec 25
Sudeep Pharma Q2 Results: EBITDA Drops 12.6% to ₹55.5 Cr, Margin Shrinks
Sudeep Pharma Limited reported Q2 financial results showing revenue growth of 6.7% to ₹162.80 crores, but faced significant profitability pressures with EBITDA declining 12.6% to ₹55.50 crores and EBITDA margin compressing to 34.09% from 42.66% year-on-year. Net profit also decreased 6.2% to ₹45.70 crores, indicating operational challenges despite top-line growth.
15
Dec 25
Sudeep Pharma Completes Q2FY26 Results Publication in Newspapers
Sudeep Pharma Limited completed regulatory compliance by publishing its Q2FY26 financial results extract in newspapers on December 20, 2025. The company reported consolidated revenue of ₹16,266.62 crores and net profit of ₹4,677.82 crores, with detailed results available on stock exchanges and company website.
Sudeep Pharma
644.
20
+
12.
60
(+
1.
99
%)
1 Year Returns:
-16.79%
Industry Peers
Sun Pharmaceutical
1,731.80
(-
0.
03
%)
Divis Laboratories
6,255.50
(-
0.
60
%)
Torrent Pharmaceuticals
4,397.90
(+
2.
10
%)
Dr Reddys Laboratories
1,300.20
(-
0.
55
%)
Cipla
1,326.70
(+
0.
02
%)
Lupin
2,250.20
(+
0.
39
%)
Zydus Life Science
903.85
(-
0.
45
%)
Mankind Pharma
2,054.70
(+
0.
40
%)
Aurobindo Pharma
1,164.40
(+
1.
20
%)
Alkem Laboratories
5,495.50
(+
0.
09
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation